Australia markets closed

OptiNose, Inc. (OPTN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.16000.0000 (0.00%)
At close: 04:00PM EDT
1.1400 -0.02 (-1.72%)
After hours: 06:48PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.1600
Open1.1800
Bid1.1400 x 400
Ask1.1900 x 200
Day's range1.1300 - 1.1800
52-week range0.8000 - 2.1000
Volume304,565
Avg. volume1,210,132
Market cap131.125M
Beta (5Y monthly)-0.10
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

    YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A

  • GlobeNewswire

    Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights

    Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million Company expects peak year XHANCE net revenues of at least $300 million from current specialist focused prescriber audience Company expects to produce positive income from operations (GAAP) for full year 2025 Conference call and webcast to be held today at 10:00 a.m. Eastern Time YARDLEY, Pa., May 14, 2024 (GLOB

  • GlobeNewswire

    Optinose Announces Reporting Date for First Quarter 2024 Financial Results

    Conference Call and Webcast to be held May 14, 2024, at 10:00 a.m. Eastern TimeYARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company’s leadership team will host a conf